Zhang Qiuning, Shao Lihua, Tian Jinhui, Liu Ruifeng, Geng Yichao, Liao Yiran, Luo Hongtao, Ge Long, Feng Shuangwu, Wang Xiaohu, Yang Zhen
Department of Radiation Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou 730050, China.
Transl Cancer Res. 2019 Aug;8(4):1381-1394. doi: 10.21037/tcr.2019.07.41.
Stereotactic body radiotherapy (SBRT) has been increasingly recognized as a favourable alternative to surgical resection for early-stage non-small cell lung cancer (NSCLC). Many retrospective analyses compared the efficacy of SBRT with that of surgery for NSCLC. However, the difference in efficacy between SBRT and surgery in patients with early-stage NSCLC remains unclear.
We searched PubMed, the Cochrane Library, EMBASE and the Chinese Biomedical Literature Database from inception to March 14, 2018, to identify studies comparing SBRT with surgery in the treatment of stage I/II NSCLC. STATA 12.0 software was used to perform the meta-analysis.
A total of 15 studies that carried out propensity score matching (PSM) were included. In this meta-analysis, patients with SBRT had worse overall survival (OS) than those with surgery, but the analysis restricting studies to the same adjustment factors showed that the difference in OS gradually decreased with the increase in comparable matching characteristics between the two groups and that there was eventually no significant difference. Patients treated with SBRT achieved similar cause-specific survival (CSS), local control, regional control, loco-regional control, and distant control compared with surgery. In addition, a separate analysis of 6 studies that compared SBRT with lobectomy also showed that with the increase in comparable matching characteristics between surgery and SBRT, the OS differences gradually decreased, and there was eventually no significant difference.
In this study, we found more favourable OS for stage I/II NSCLC treated with surgery, but when there were increasing numbers of comparable matching characteristics between surgery and SBRT, the differences in the survival rate were reduced to the point that they were not significant. The CSS and recurrence (local, regional, or disseminated) differences between surgery and SBRT were also not significant. Therefore, SBRT has the potential to be an alternative to surgical treatment in patients with stage I/II NSCLC, but these findings need to be confirmed by large-sample, long-term follow-up randomized clinical studies.
立体定向体部放疗(SBRT)已越来越被认为是早期非小细胞肺癌(NSCLC)手术切除的一种有利替代方案。许多回顾性分析比较了SBRT与手术治疗NSCLC的疗效。然而,早期NSCLC患者中SBRT与手术疗效的差异仍不明确。
我们检索了PubMed、Cochrane图书馆、EMBASE和中国生物医学文献数据库,检索时间从建库至2018年3月14日,以识别比较SBRT与手术治疗I/II期NSCLC的研究。使用STATA 12.0软件进行荟萃分析。
共纳入15项进行倾向评分匹配(PSM)的研究。在这项荟萃分析中,接受SBRT治疗的患者总生存期(OS)比接受手术治疗的患者差,但将研究限制在相同调整因素的分析表明,随着两组间可比匹配特征的增加,OS差异逐渐减小,最终无显著差异。与手术相比,接受SBRT治疗的患者在特定病因生存率(CSS)、局部控制、区域控制、局部区域控制和远处控制方面相似。此外,对6项比较SBRT与肺叶切除术的研究进行单独分析也表明,随着手术与SBRT间可比匹配特征的增加,OS差异逐渐减小,最终无显著差异。
在本研究中,我们发现I/II期NSCLC接受手术治疗有更有利的OS,但当手术与SBRT间可比匹配特征数量增加时,生存率差异减小至无显著意义。手术与SBRT在CSS和复发(局部、区域或播散性)方面的差异也不显著。因此,SBRT有可能成为I/II期NSCLC患者手术治疗的替代方案,但这些发现需要通过大样本、长期随访的随机临床研究来证实。